Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Natural Product Derivatives Kill Dental Cavity Causing Streptococcal Strains

Description:

 

Brief Description:  Antibiotics, Dental Cavities, Therapeutics, Oral Bacteria, Honokiol

 

Technology

 

Problem:

Early colonizers of dental bacterial infections, such as Streptococcus sanguinis and Streptococcus gordonii, are responsible for early plaque formation by anchoring adhesion proteins to the pellicle of the tooth and producing glucan polymers that constitute the matrix of dental plaque. Streptococcus mutans is able to invade this matrix to form microcolonies and eventually develop the mature biofilm that is responsible for tooth decay and acidification. To date, few natural products (such as carolacton) have been reported to be effective inhibitors of S. mutans growth, many of which are difficult to synthesize.

 

Solution:

A novel set of compounds with bactericidal activity against oral Streptococcal infections, including S. mutans, S. sanguinis, and S. gordonii. The compounds were inspired by reports of antimicrobial activity of honokiol, a natural product from Magnolia trees. A recently published journal article in ACS Infectious Diseases from Marisa Kozlowski’s laboratory at the University of Pennsylvania’s Department of Chemistry, and in collaboration with Professor William Wuest at Emory University, describes synthetic routes to novel compounds that contain linked phenolic motifs with bactericidal activity towards oral Streptococcal strains. Under previously untested, physiologically relevant conditions, the Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) values for identified analogs were two orders of magnitude lower than honokiol, the previously investigated natural product.

 

Applications:

•       Dental Cavity Prevention (toothpastes, oral rinses, etc.)

•       Topical Antibiotic Applications

•       Antibacterial Soaps

 

Advantages:

•       Simple Synthesis

•       Lower MIC and MBC than previously reported antibiotics

•       Effective against multiple Streptococcal species

  

Stage of Development:

•       Screening against additional bacterial strains

•       Development of additional derivative compounds

 

Intellectual Property:

Provisional Pending

 

Reference Media:

Solinksi, A.E. et al. ACS Infect. Dis., 2017, DOI: 10.1021/acsinfecdis.7b00178

 

Desired Partnerships:

1.       License

2.       Co-development  

 

Docket # 18-8456


Patent Information:
For Information, Contact:
Qishui Chen
University of Pennsylvania
215-898-9591
qchen1@upenn.edu
Inventors:
Marisa Kozlowski
William Wuest
Keywords: